Bafna Pharmaceuticals Limited Market Cap ($116.28 Million)
Market Cap & Net Worth: Bafna Pharmaceuticals Limited (BAFNAPH)
Bafna Pharmaceuticals Limited market cap. Bafna Pharmaceuticals Limited (NSE:BAFNAPH) has a market capitalization of $116.28 Million (Rs10.75 Billion) as of November 8, 2026. Listed on the NSE stock exchange, this India-based company holds position #18377 globally and #992 in its home market, demonstrating a -0.55% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Bafna Pharmaceuticals Limited's stock price Rs454.50 by its total outstanding shares 23656335 (23.66 Million). Also see BAFNAPH cash generation efficiency for how efficiently the company converts equity into cash flow.
Bafna Pharmaceuticals Limited Market Cap History (2015–2026)
Bafna Pharmaceuticals Limited market cap history from 2015 to 2026. Data shows growth from $115.25 Million to $116.28 Million (1.36% CAGR). Check today's stock price for Bafna Pharmaceuticals Limited for real-time trading data and today's change.
Bafna Pharmaceuticals Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Bafna Pharmaceuticals Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore BAFNAPH net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.08x
Bafna Pharmaceuticals Limited's market cap is 0.08 times its annual revenue
Latest Price to Earnings (P/E) Ratio
1.05x
Bafna Pharmaceuticals Limited's market cap is 1.05 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $72.02 Million | $649.62 Million | -$190.87 Million | 0.11x | N/A |
| 2018 | $29.55 Million | $471.71 Million | -$167.37 Million | 0.06x | N/A |
| 2019 | $9.08 Million | $436.27 Million | -$188.71 Million | 0.02x | N/A |
| 2020 | $43.71 Million | $424.73 Million | -$18.78 Million | 0.10x | N/A |
| 2021 | $35.48 Million | $712.18 Million | $58.27 Million | 0.05x | 0.61x |
| 2022 | $25.78 Million | $851.40 Million | $52.16 Million | 0.03x | 0.49x |
| 2023 | $23.54 Million | $1.15 Billion | $113.38 Million | 0.02x | 0.21x |
| 2024 | $20.19 Million | $1.52 Billion | $73.48 Million | 0.01x | 0.27x |
| 2025 | $38.56 Million | $1.46 Billion | $41.52 Million | 0.03x | 0.93x |
| 2026 | $116.28 Million | $1.51 Billion | $111.00 Million | 0.08x | 1.05x |
Competitor Companies of BAFNAPH by Market Capitalization
Companies near Bafna Pharmaceuticals Limited in the global market cap rankings as of November 8, 2026. Also see Bafna Pharmaceuticals Limited asset portfolio for a full breakdown of the balance sheet.
Key companies related to Bafna Pharmaceuticals Limited by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #511 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #530 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #567 globally with a market cap of $47.07 Billion USD ( CN¥321.69 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #609 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #511 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #530 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.61 |
| #567 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $47.07 Billion | CN¥50.43 |
| #609 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.80 |
Market Capitalization of Bafna Pharmaceuticals Limited (2015–2026)
Market capitalization of Bafna Pharmaceuticals Limited from 2015 to today. Between 2015 and today, Bafna Pharmaceuticals Limited's market cap moved from $115.25 Million to $ 116.28 Million, with a yearly change of 1.36%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Rs116.28 Million | +201.55% |
| 2025 | Rs38.56 Million | +91.03% |
| 2024 | Rs20.19 Million | -14.24% |
| 2023 | Rs23.54 Million | -8.68% |
| 2022 | Rs25.78 Million | -27.36% |
| 2021 | Rs35.48 Million | -18.82% |
| 2020 | Rs43.71 Million | +381.27% |
| 2019 | Rs9.08 Million | -69.26% |
| 2018 | Rs29.55 Million | -58.97% |
| 2017 | Rs72.02 Million | -2.43% |
| 2016 | Rs73.81 Million | -35.96% |
| 2015 | Rs115.25 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 8th, 2026 the market cap of Bafna Pharmaceuticals Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $116.28 Million USD |
| MoneyControl | $116.28 Million USD |
| MarketWatch | $116.28 Million USD |
| marketcap.company | $116.28 Million USD |
| Reuters | $116.28 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Bafna Pharmaceuticals Limited
Bafna Pharmaceuticals Limited manufactures and sells finished pharmaceutical formulations in India. It also exports its products to Europe, the United Kingdom, Australia, Sri Lanka, Africa, Philippines, Tanzania, Nigeria, and Commonwealth countries. Bafna Pharmaceuticals Limited was founded in 1981 and is based in Chennai, India. Bafna Pharmaceuticals Limited is a subsidiary of SRJR Lifesciences … Read more